A Phase 1/2 Study of MRT-2359 in People with Advanced Lung Cancer and Other Solid Tumors


Full Title

A Phase 1/2, Open-label, Multicenter Study of Oral MRT-2359 in Patients with MYC-driven and Other Selected Solid Tumors Including Lung Cancer and Diffuse Large B-cell Lymphoma


In this study, researchers want to find the highest dose of the investigational drug MRT-2359 that can be given safely in people with advanced lung cancer and other solid tumors. MRT-2359 targets a protein that helps cancer cells grow. By attaching to and destroying that protein, MRT-2359 may cause cancer cells to die. It is taken orally (by mouth).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have advanced non-small cell lung cancer, small cell lung cancer, neuroendocrine cancer, or a solid tumor with elevated activity of the L-MYC or N-MYC proteins.
  • At least 3 weeks must pass between the completion of prior anticancer therapies and receipt of MRT-2359.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.


For more information and to ask about eligibility for this study, please contact the office of Dr. Noura Choudhury at 646-608-3762.




Phase I/II (phases 1 and 2 combined)

Disease Status

Relapsed or Refractory


ClinicalTrials.gov ID